Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,375 INR | +1.87% | +7.63% | -7.76% |
Mar. 18 | Dr Lal Pathlabs Names CEO | MT |
Mar. 17 | Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 54.48 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.76% | 2.32B | B | ||
-17.89% | 8.36B | B+ | ||
+40.49% | 3.6B | C+ | ||
-32.64% | 2.73B | B- | ||
-7.88% | 2.47B | - | ||
-14.40% | 1.77B | C- | ||
-18.74% | 1.55B | A- | ||
-40.19% | 1.22B | C+ | ||
+5.57% | 1.09B | B+ | ||
-15.34% | 1.03B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LALPATHLAB Stock
- LALPATHLAB Stock
- Ratings Dr. Lal PathLabs Limited